Introduction {#sec1-1}
============

The great clinical and functional benefit of total hip arthroplasty (THA) for patients undergoing total hip replacement, but also the socioeconomic significance of the restoration of the more and more young and still working patients with disabling hip diseases for health systems have been demonstrated in many studies during the last decades. It is therefore not amazing that THA was elected as *operation of the 20th century.*^[@ref1]^

Relevant improvements in implant design, the progress in the biomaterials and articulating surfaces, the development of the instruments and the used surgical techniques have lead to excellent implant survivorship rates during the first 10 years after THR. However, aseptic loosening by wear debris particles still remains a major problem in long-term follow-up. The small particles generated by wear of the articulating surfaces initiate a local inflammation including release of IL-3, IL-6 and TNF-alpha, followed by an activation of the MAP kinase cascades, and the RANK/RANKL system. Beginning at the proximal part of the joint, activated osteoclasts promote osteolysis which may lead to micromotion or fracture resulting in implant failure.^[@ref2]^

Metal-on-metal articulations demonstrated high rates of metal ion concentration, especially in large femoral head articulations and in cases of suboptimal implant positioning. Local immunoreactions have been observed \[*pseudotumors*, adverse local tissue reaction (ALTR), aseptic lymphocytic vasculitis-associated lesion (ALVAL)\],^[@ref3]^ and have led to a heightened interest in alternative articulation materials like ceramics and polyethylene.

Polyethylene (PE) liners in hip arthroplasty have been introduced in the late 50ies and since that time, has been modified several times over the last decades ([Figure 1](#fig001){ref-type="fig"}).

In 1958, the first polymer liner which was successfully applied in THR was polytetrafluoroethylene (PTFE, teflon), a relatively soft material which showed relevant cold flow and poor resistance to wear and delamination in the 1960s.

Based on these poor material properties resulting in high wear and fracture rates, ultra-high molecular weight polyethylene (UHMWPE) sterilized by radiation in air was introduced in 1962 (traditional UHMWPE).^[@ref7],[@ref8]^

While the traditional UHMWPE seemed to be superior to PTFE, the problem of implant failure caused by relevant wear was still unsolved. In the 1980s, further improvements in material properties have been achieved since UHMWPE was sterilized in an inert atmosphere (conventional UHMWPE).

Introduced in the late 1980s, UHMWPE has demonstrated a superior durability in mid- and long-term. With a growing understanding of the significance of wear debris at a nano- and micrometer level as cause of aseptic loosening (particle disease), hardening of the PE was believed to increase long-term implant survivorship.

In the 1990s, the first attempt to solve this problem by developing an *enhanced UHMWPE* (Hylamer®) failed. Produced with high pressure and temperature it was thought that changing the crystalline structure to extended chains might enhance the physical properties of UHMWPE, including an increased resistance to abrasion. However, based on extensive wear and associated peri-implant osteolysis, Hylamer® had to be recalled.^[@ref9],[@ref10]^

The second attempt to make the material more resistant to wear resulted in additional cross-linking of UHMWPE (UHMPWE-X) by gamma irradiation or electrobeam in the early 2000.^[@ref11]^ The positive or negative effects of UHMWPE-X versus conventional UHMWPE are still controversially discussed in the scientific community and strongly dependent on the manufacturing process.

Some authors report an increased wear during the first 2 years (running-in period), but afterwards the data correspond to *in vitro* data (simulator).^[@ref12]^ Also the risk of fatigue cracks seems to be little higher in some types of UHMWPE-X compared to conventional UHMWPE. However, there is no evidence that smaller particles released from UHMWPE-X increase the risk of osteolysis. Therefore, besides UHMWPE-X conventional UHMWPE still is used in THA to date.

Although different optimization steps in polyethylene development have lead to excellent implant survivorship within the first 10-15 years, the problem of material ageing caused by progressive oxidation was still unsolved as has been shown by analysis of explanted liners.^[@ref13]^ The clinical consequence of the oxidation is an increased wear rate starting approximately 10 years postoperative. Encouraged by promising in vitro results, today several acetabular inserts are supplemented with antioxidants.^[@ref16]^ Different technical approaches have been realized for the manufacturing process (coating, diffusion, covalent binding, embedding/blending).^[@ref22]^ Beside other substances, Vitamin-E (alpha-tocopherol) seems to be a promising candidate,^[@ref23],[@ref24]^ as it is inert and has shown no relevant side effects in low concentrations in humans.

The oxidation is a relevant parameter concerning the long-term survival of the PE-material. Evaluation of standard PE-liners have shown that oxidative processes changes the material. While the PE evolves and gets more refractory, at first the wear rates improve in comparison to Vitamin-E stabilized UHMWPE-XE. In the following however, the growing brittleness leads to a higher wear and consequently higher implant failure rates.

It is yet unclear if antioxidants improve UHMWPE durability *in vivo* by reducing oxidation and show less abrasion in the long-term. Also the question of increased wear of UHMWPE-XE during the first years after implantation by modifications of the polymer texture arises.^[@ref25]^ To date there are no clinical data available comparing UHMWPE-X with UHMWPE-XE in total hip arthroplasty liners. An in vivo evaluation of the oxidation of the PE material is not possible. Therefore, in this study, the oxidation index of PE-liners with and without Vitamin-E of revised cases shall be assessed, accompanied by a comparison of long-term clinical and functional results.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

Patients, men and women, with the indication for a cementless total hip arthroplasty, aged 18 to 75 years are asked to participate in the study. Exclusion criteria are a heightened narcosis risk (ASA IV), tumors, drug or alcohol addiction, permanent cortisone therapy, clinically relevant infections, pregnancy or planned pregnancy, fractures, previous surgeries at the concerned hip (osteotomy, osteosynthesis, THA), a bone quality indicating a cemented implantation, relevant deformities (status after previous treatment like leg length differences \>30 mm, offset reductions \>30 mm), indications for non-ceramic heads or small cups needing 28 mm heads, treatments where a neck-extension is indicated. According to the Declaration of Helsinki informed consent of every patient is obtained prior to surgery in a written form.

The patients are recruited in all 6 participating hospitals. No definitions regarding a limitation of surgeons treating the study patients have been set up. The surgeon is informed by the study coordinator of his center on the randomization result, *i.e.* if standard highly crosslinked UHMWPE-X is used or Vitamin-E supported UHMWPE-XE ([Figure 2](#fig002){ref-type="fig"}). The study was approved by the ethics committee of the (\#11-4845-BO) and is conducted according to the common guidelines for clinical trials (Declaration of Helsinki). The trial registration number is NCT01713062. Informed consent is obtained for all patients. The trial is in the recruitment phase.

Study design {#sec2-2}
------------

In 2011 we initiated a prospective and randomized multicenter study evaluating a CE-marked vitamin-E supplemented UHMWPE-XE (Vitelene®) *versus* UHMWPE-X ([Figure 3](#fig003){ref-type="fig"}), the *Longterm-Evaluation of Vitelene® Against Standard* (VITAS®, sponsor: B.Braun-Aesculap AG, Tuttlingen, Germany). Six study centers are participating, recruiting 400 patients within a planned recruiting till end of 2014. The randomization has been calculated as block randomization with random block length, stratified by center (SAS 9.2). The random numbers are accessed by the study centers via a SSL- secured online database. The study has a planned follow-up period of 15 years, aiming for long-term results.

Intervention {#sec2-3}
------------

Patients treated with a cementless THA are randomized to receive either a Vitelene® liner or a standard PE liner. Plasmacup DC® (Aesculap, Tuttlingen, Germany), a cementless hemispheric cup with a microporous titanium coating (Plasmapore®) is used. Which cementless stem is used, if standard or short stem, the surgical technique and approach are left open to the choice of the surgeon. To eliminate the influence of different head materials or head sizes, Biolox® delta heads (Ceramtec, Plochingen, Germany) with 32 or 36 mm have been determined to be used for study patients. The intraoperative and postoperative medication and treatment of the study patients has not been defined and will correspond to the routine of the study centers.

Follow-up and outcome parameters {#sec2-4}
--------------------------------

VITAS has been designed as prospective, randomized long-term evaluation of Vitamin-E supplemented highly cross-linked UHMWPE liners in comparison to standard highly cross-linked UHMWPE liners. The study has been set up for 15 years, with follow-ups after 1, 5, 10 and 15 years. Since projects with such long-term evaluation tend to have difficulties with high rates of loss of follow-up, it is planned to contact the study participants in the interim time by writing to stay informed on their status of health and to not loose the relationship.

The aim of the study is to evaluate the superiority of UHMWPE-XE in comparison to UHMWPE-X in regards to oxidation. To determine the efficiency of Vitamin-E as an antioxidant, the oxidation index (OI) in retrieved liners of revised patients has been set as primary parameter. To this end, all liners harvested during revision surgeries will be washed in sterile saline water, stored in special set up transport boxes and sent to the sponsor for the laboratory evaluation (oxidation index). The oxidation index is assessed with the Fourier-Transform-Infrared-Spectroscopy (FTIR -- ISO 5834.1/.2 -- *Implants for surgery* - *Ultra-high molecular weight polyethylene*), where the absorption of the infrared wavelength is measured.

In addition, clinical and radiological results will be obtained as secondary parameters. Linear wear (≥0.5 mm) will be evaluated on routinely taken conventional radiographs after 5, 10 and 15 years with the Martell Hip Analysis Suite®,^[@ref12],[@ref26],[@ref27]^ that is able to detect cumulated linear wear rates of 0.3 mm. A recognized critical value for wear in regard to consequent osteolysis is 0.1 mm per year.^[@ref28]^

Evaluation of standard radiographs for manifest osteolysis will be done additionally to the measurement of the cumulated wear rates. X-rays will be analyzed for osteolytic changes according to Gruen *et al*.^[@ref29]^ Other radiological parameters like migration, implant position and ossifications according to Brooker *et al*.^[@ref30]^ will be assessed and documented.

Functional outcome, the well-being of the patient in daily-life activities is assessed with the Harris Hip Scores (HHS) and with the Hip Disability and Osteoarthritis Outcome Score (HOOS).^[@ref31],[@ref32]^ The level of activity is measured with the UCLA Score (University of California, Los Angeles).^[@ref33],[@ref34]^ [Table 1](#table001){ref-type="table"} summarizes different parameters.

Statistical calculations and biometry {#sec2-5}
-------------------------------------

We expect a significant lower oxidation index for retrieved UHMWPE-XE liners in contrast to UHMWPE-X liners. Under the assumption of comparable revision rates in both groups, the two-sample t-test for mean difference with unequal variances gives a case number of 15 explants per group. Under consideration of the multicenter situation and the 15 years follow-up, a drop-out rate of 25% is assumed, leading to 20 explants per group. With a revision rate of 10% in 15 years, 400 patients will be needed to get 40 revision cases. Evaluation of endpoints is planned as per-protocol analysis. Statistical tests and presentation will be appropriate to the category and distribution of the respective variables. The test level for statistical significance is defined as P=0.05, two sided, for all tests.

Discussion {#sec1-3}
==========

*In vivo* evaluation of implanted liners in THA is not possible without an invasive procedure. Therefore, the laboratory evaluation of explanted liners in revision cases has been chosen as primary criteria for the assessment of the influence of Vitamin-E on the oxidation process of the PE-material.

While a controlled setting is relevant to eliminate different influences on the outcome of the surgery *i.e.* the endpoints of the study, too strictly defined conditions generate an unrealistic situation. In this study, the high number of patients and participating clinics and surgeons and a recruiting time of almost 3 years should allow for a wide range of proceedings. Surgical technique, postoperative rehabilitation programs, medication etc. is not defined and will be done according to the regular standard in each hospital. Since head size and material are influencing the wear rate, size and material of the used head are the only specifications.

The prospective design and the randomization of the two study groups therefore should allow a scientific conclusion on the influence of the antioxidant in every day conditions.

Conclusions {#sec1-4}
===========

The analysis of the retrieved implants should grant distinct results for the evaluation of highly cross-linked UHMWPE-X in comparison to Vitamin-E stabilized highly cross-linked UHMWPE-XE. Additional evaluation of radiographic wear, osteolysis and migration as well as the functional results of the every-day life of the patient will allow a long-term evaluation of the two biomaterials, one state of the art today, the other an option with promising, results.

Appendix: the VITAS Group {#sec1-5}
=========================

The VITAS™ study is financially supported by the sponsor (B.Braun-Aesculap AG, Tuttlingen, Germany). It is composed by: Christoph von Schulze Pellengahr (Director); Georgious Spyrou (Orthopaedic and Trauma Department, St. Josef Hospital, University of Bochum, GERMANY); Karl-Stefan Delank (Director); Sven Freche (Orthopaedic Department, University of Halle, Germany); Henning Windhagen (Director); Gabriele v. Lewinski, Thilo Flörkemeier, Stefan Budde (Orthopaedic Department, Hannover Medical Center, Germany); Axel Wilke (Orthopaedistin-Chief), Felix Hütter (Orthopaedic and Trauma Department, Elisabeth Hospital, Olsberg, Germany); Joern Michael (Orthopaedist-in-Chief); Dominik Mehlen (Orthoapedic and Trauma Department, St. Josef Hospital, Bendorf, Germany).

![Evolution of polyeethylenes in total hip arthroplasty.](or-2014-2-5285-g001){#fig001}

![Different colors with UHMWPE-X and UHMWPE-XE (Vitelene™).](or-2014-2-5285-g002){#fig002}

![Patient recruitment.](or-2014-2-5285-g003){#fig003}

###### 

Parameters and methods.

  Oxidation-index                             Retrieval analysis
  ------------------------------------------- --------------------------------------------------------------------------------------------------------
  Implant survivorship                        Amount of aseptic loosenings and revisions
  Radiological results                        Osteolysis; wear rates
  Functional results                          Harris Hip Score; Hip Disability and Osteoarthritis Score; Universisty of California-Los Angeles Score
  Pain level                                  Visual Analogue Scale
  Intra- and post-operative complications     Interview, medical reports and records
  Surgical technique and implant components   Medical reports and records
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